Click Here for Session Questions: Q&A 

SESSION II: MYELODYSPLASTIC SYNDROMES

Session Chair: Guillermo Garcia-Manero and Rami Komrokji

Molecular and Cellular Basis of MDS | Simona Colla, PhD | MD Anderson Cancer Center, Houston, Texas, USA

Progress in Lower Risk MDS | Valeria Santini, MD | University of Florence, Florence, Italy

Progress in Higher Risk MDS | David Valcárcel Ferreiras, MD, PhD | Vall d'Hebron University Hospital, Barcelona, Spain

Transplant in MDS | Sergio Giralt, MD | Memorial Sloan Kettering Cancer Center, New York, New York, USA

An International Perspective of Progress in MDS | Pierre Fenaux, MD, PhD | Hôpital Saint Louis, Paris, France

Oral Abstract | MDS-157: Overall Survival (OS), Clinical Benefit, and Durable Red Blood Cell (RBC) Transfusion Independence (TI) With Imetelstat in the IMerge Phase 3 Trial of RBC-Transfusion Dependent (TD) Lower-Risk Myelodysplastic Syndromes (LR-MDS) | Valeria Santini, MD | University of Florence, Florence, Italy